STRATIFY-StatinMD Risk Calculator

Researchers at the University of Oxford have developed a new clinical prediction tool, the STRATIFY-StatinMD Risk Calculator, designed to estimate an individual's risk of developing serious muscle disorders from statin therapy. Published in The Lancet Digital Health on June 25, 2026, the study addresses the widespread patient hesitation regarding statins due to fears of side effects, providing a personalized risk assessment that balances potential harms against the significant benefits of preventing heart attacks and strokes. The authors emphasize that for over 98% of eligible patients, the risk of serious muscle-related complications is extremely low. By utilizing data from over 5.6 million health records, the model incorporates 22 distinct health factors to move beyond population averages. This approach aims to bridge the treatment gap, as currently more than 60% of individuals who qualify for statin therapy remain untreated, often due to unfounded concerns about muscle pain. The calculator serves as a strategic decision-support tool for clinicians and patients, intended to be used alongside existing cardiovascular risk assessment tools like QRISK. It provides a transparent, evidence-based framework to facilitate informed discussions about monitoring, alternative treatments, or the safety of proceeding with standard therapy. Users can leverage this tool to gain clarity on their specific health profile, reducing anxiety caused by general misconceptions. It is recommended that patients discuss these personalized results with their healthcare providers to make balanced, data-driven decisions regarding their long-term cardiovascular health and medication adherence.